Table 1.
Patient characteristics
| Variables | All patients (n = 81) | BNP ≤ 61.4 pg/mL (n = 41, 50.6%) | BNP > 61.4 pg/mL (n = 40, 49.4%) | P‐value |
|---|---|---|---|---|
| Age, years | 74.1 ± 6.8 | 72.2 ± 8.1 | 76.3 ± 4.4 | 0.005 |
| Men, n | 41 (50.6) | 24 (58.5) | 17 (42.5) | 0.185 |
| Body mass index, kg/m2 | 23.4 ± 2.7 | 23.3 ± 2.2 | 23.5 ± 3.2 | 0.805 |
| Hypertension, n | 55 (67.9) | 25 (61.0) | 30 (75.0) | 0.235 |
| Diabetes mellitus, n | 14 (17.3) | 6 (14.6) | 8 (20.0) | 0.569 |
| Dyslipidaemia, n | 41 (50.6) | 21 (51.2) | 20 (50.0) | 1.000 |
| eGFR a , mL/min/1.73 m2 (n = 74) | 63.7 ± 20.8 | 70.9 ± 20.1 | 55.1 ± 18.3 | 0.001 |
| Chronic kidney disease, n | 41 (50.6) | 14 (34.1) | 27 (67.5) | 0.004 |
| Haemodialysis, n | 7 (8.6) | 1 (2.4) | 6 (15.0) | 0.057 |
| BNP, pg/mL (median) | 61.4 (29.7–109.9) | 29.7 (21.9–45.9) | 115.1 (78.2–237.4) | <0.001 |
| Atrial fibrillation/flutter, n | 17 (21.0) | 8 (19.5) | 9 (22.5) | 0.790 |
| Previous myocardial infarction, n | 10 (12.3) | 2 (4.9) | 8 (20.0) | 0.048 |
| Previous PCI, n | 27 (33.3) | 10 (24.4) | 17 (42.5) | 0.102 |
| Previous CABG, n | 4 (4.9) | 1 (2.4) | 3 (7.5) | 0.359 |
| Peripheral arterial disease, n | 14 (17.3) | 3 (7.3) | 11 (27.5) | 0.020 |
| Chronic lung disease, n | 27 (33.3) | 10 (24.4) | 17 (42.5) | 0.102 |
| Previous stroke, n | 5 (6.2) | 4 (9.8) | 1 (2.5) | 0.359 |
| NYHA functional class | 0.054 | |||
| I, n | 57 (70.4) | 33 (80.5) | 24 (60.0) | |
| II, n | 24 (29.6) | 8 (19.5) | 16 (40.0) | |
| III/IV, n | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Medication | ||||
| Beta‐blocker, n | 12 (14.8) | 4 (9.8) | 8 (20.0) | 0.226 |
| ACEi/ARB, n | 38 (46.9) | 16 (39.0) | 22 (55.0) | 0.184 |
| Mineralocorticoid receptor antagonist, n | 12 (14.8) | 4 (9.8) | 8 (20.0) | 0.226 |
| Loop diuretic, n | 16 (19.8) | 5 (12.2) | 11 (27.5) | 0.100 |
| Aspirin, n | 42 (51.9) | 16 (39.0) | 26 (65.0) | 0.026 |
| Oral anticoagulant, n | 13 (16.0) | 7 (17.1) | 6 (15.0) | 1.000 |
ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B‐type natriuretic peptide; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
Continuous data are presented as means ± standard deviations, except BNP (median and interquartile range); categorical data are given as the counts (percentages).
a
eGFR was indicated in patients without haemodialysis.